SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore-based leading non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced its plans to create an integrated digital health and rewards platform which will use a utility cryptocurrency called QB. The QB coins are being developed by a third party, and are scheduled to be launched sometime in January 2026 for use in EUDA's digital health and wellness ecosystem. A Tradeable Healthcare Utility Cryptocurrency with Real-World Application and Value EUDA will create a platform where QB can be used for payments, rewards, and access t

SINGAPORE, Dec. 05, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or "the Company"), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it entered into a securities purchase agreement on November 26, 2025 with Streeterville Capital, LLC, a Utah limited liability company, for the sale of a convertible warrant (the "Warrant") for an aggregate purchase price of US$100,000. The Warrant is exercisable for up to 2,000,000 newly issued EUDA ordinary shares (the "Warrant Shares") at an exercise price of US$6.00 per share and is being offered pursuant to the Company's effective shelf registration

SINGAPORE, Oct. 23, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, CK Health Plus Sdn. Bhd. ("CK Health Plus"), will expand into the Indian market through a strategic master license and representative partnership with SafeRock India Private Limited ("SafeRock India"), a SafeRock India Private Limited leading systems integration and infrastructure solutions companies in India. Market Opportunity and Growth Potential India is emerging as one of the most dynamic frontiers in the global wellnes

SINGAPORE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, CK Health Plus Sdn. Bhd. ("CK Health Plus"), has been granted a Direct Selling License (AJL 932509) (the "License") by the Malaysian Ministry of Domestic Trade and Cost of Living. License Approval and Compliance The License marks a major milestone for CK Health Plus, allowing it to compliantly conduct direct selling and multi-level marketing operations nationwide. CK Health Plus is now authorized to recruit members, distribu

SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. ("EUDA Health"), has signed a Letter of Intent (the "LOI") to potentially acquire GO POSB Organoids Pte Ltd ("GO POSB"), a biotechnology company formed in Singapore. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that reprograms human blood cells into clinical-grade, therapeutics-ready stem cells. These iPSCs can differentiate into nearly any cell type in the human bo

SINGAPORE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" or the "Company") (NASDAQ:EUDA), a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced that it has secured distribution rights for T-cell immunotherapies in Malaysia developed by Shenzhen Inno Immune Co. Ltd. ("Shenzhen Inno"), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in China. These T-cell immunotherapies are designed to restore and rebuild the body's natural defenses. This marks EUDA's second major step into advanced cell therapy this year, following its April 2025 dist

SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the "LOI") to potentially acquire Chemokine Pte Ltd ("Chemokine"). EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty (120) days during which it shall not engage in any discussions with any other entity relating to any transaction similar to this potential acquisition. Chemokine is a Singapore ba

SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the "Supplement") from Chemokine Pte. Ltd. ("Chemokine"), a Singapore-based biotech company focused on molecular supplements and gene modulating formulations. EUDA and its subsidiaries will market and sell the Supplement under the brand name, Euda Helixé, initially in Singapore, Malaysia, and Chi

SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" or the "Company") (NASDAQ:EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. ("Guangdong Cell Biotech"). Guangdong Cell Biotech is a prominent player in stem cell therapies and regenerative medicine in China. It develops autologous cell treatments and tailored medicines for various disorders. Instead of the initially contemplated joint venture, the parties have adopted a commercial

-        Preliminary Discussions Underway to Establish a Joint Venture SINGAPORE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" or the "Company") (NASDAQ:EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it has entered into preliminary discussions with Guangdong Cell Biotech Co. Ltd. ("Guangdong Cell Biotech"), a prominent player in stem cell therapies and regenerative medicine, to form a joint venture. Guangdong Cell Biotech develops autologous cell treatments and tailored medicines for various disorders. This potential collaboration aims to leverage the complem

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

424B5 - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

6-K - EUDA Health Holdings Ltd (0001847846) (Filer)

SC 13G - EUDA Health Holdings Ltd (0001847846) (Subject)